// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Trans and/or non-binary (TNB parents’ experiences during the perinatal period

S Bower-Brown - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The effect of ethnicity on ovarian stimulation outcomes of altruistic oocyte donors from the largest UK vitrified egg bank: a retrospective cohort study

D Bodri - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Buserelin

Outcomes of Ovarian Drilling

O Nwachukwu - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Ovarian hyperstimulation syndrome

clomiphene

Optimal route of progesterone administration for luteal phase support in frozen embryo transfer cycle : systematic review

A Almohammadi - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

NLRP3 Inflammasome and polycystic ovarian syndrome – a possible novel association

S Amer - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Polycystic Ovary Syndrome

N/A

Predicting the Number of Oocytes Retrieved from Controlled Ovarian Hyperstimulation with Machine Learning

J Chambost - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Ovarian hyperstimulation syndrome

N/A

Patient Experience of fertility treatment in the UK

J Darragh - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Exploring representation and inclusivity in fertility and reproductive health societies’ leadership

N Usman - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Factors associated with live birth rate (LBR and multiple live birth rate (mLBR: UK vs France registries

N Karpaviciute - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Mode of conception and pregnancy outcomes: systematic review and meta-analysis of 110 studies and 33,655,021 singleton pregnancies

Y Beebeejaun - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Gestational Diabetes

N/A

Systematic review and meta-analysis of female lifestyle factors and risk of recurrent pregnancy loss (RPL

K.Y.B Ng - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Spontaneous abortion

Caffeine

Discriminatory value of steroid hormones on polycystic ovary syndrome in women with infertility and obesity

Z Wang - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Polycystic Ovary Syndrome

DHEA-S

Current understanding of polycystic ovary syndrome (PCOS and potential interest in future trial to evaluate role of myo-inositol as ovulation induction agent – Stakeholder’s surveys

J Pundir - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Polycystic Ovary Syndrome

Inositol

Pituitary functioning gonadotroph adenomas (FGA-induced ovarian hyperstimulation syndrome (OHSS: results from tertiary neuroendocrine centres in the UK

N Papanikolaou - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian hyperstimulation syndrome

Somatostatin

A comparison of pk and pd outcomes of tocilizumab in giant cell arteritis after sc and iv dosing

N.L. Mallalieu - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Tocilizumab

A comparison of the effectiveness of mycophenolate mofetil or methotrexate in combination with prednisolone versus prednisolone alone in the treatment of large vessel vasculitis

R. Smith - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Large vessel vasculitis

Mycophenolate mofetil

A pooled analysis of three tnf-Α inhibitor biosimilar studies in patients with rheumatoid arthritis comparing radiographic progression by disease activity states

J.S. Smolen - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab

A probability score from a fast track clinic to aid the management of suspected giant cell arteritis

F. Laskou - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Glucocorticoid

A propensity score-matched (PSM analysis of organ damage in patients with systemic lupus erythematosus (SLE from the pooled bliss long-term extension (LTE trials versus the toronto lupus cohort (TLC

M. Urowitz - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Belimumab

Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the giacta trial

J.H. Stone - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Prednisone

Copyright © 2026. QuantiNova All rights reserved